BioNano Genomics (BNGO) Ratios
BioNano Genomics Ratios
MX:BNGO's free cash flow for Q2 2026 was $-4.67M. For the 2026 fiscal year, MX:BNGO's free cash flow was increased by $0.00 and operating cash flow was $-4.67M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.98 | 1.06 | 1.40 | 4.38 | 12.47 |
| Quick Ratio | 1.74 | 0.76 | 1.17 | 3.55 | 11.91 |
| Cash Ratio | 0.13 | 0.25 | 0.18 | 0.14 | 1.13 |
| Solvency Ratio | -0.57 | -2.37 | -1.85 | -2.11 | -1.73 |
| Operating Cash Flow Ratio | -0.71 | -1.85 | -1.25 | -3.48 | -3.29 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -3.38 | -1.79 | 0.00 | 0.00 |
| Net Current Asset Value | $ 16.23M | $ -1.81M | $ 21.87M | $ 99.19M | $ 232.43M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.36 | 0.37 | 0.04 | 0.03 |
| Debt-to-Equity Ratio | 0.16 | 0.77 | 0.83 | 0.05 | 0.03 |
| Debt-to-Capital Ratio | 0.13 | 0.44 | 0.45 | 0.04 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.66 | 2.17 | 2.23 | 1.23 | 1.12 |
| Debt Service Coverage Ratio | -54.92 | -4.72 | -2.85 | -410.06 | -73.50 |
| Interest Coverage Ratio | -111.88 | -359.80 | -42.05 | -441.94 | -83.17 |
| Debt to Market Cap | 0.72 | 0.62 | 1.06 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.32 | 14.50 | 145.65 | 24.34 | 24.70 |
| Net Debt to EBITDA | -0.24 | -0.19 | -0.29 | -0.05 | 0.19 |
| Profitability Margins | |||||
| Gross Profit Margin | 21.95% | 1.23% | 26.49% | 21.38% | 21.54% |
| EBIT Margin | -91.31% | -362.93% | -629.39% | -469.08% | -429.48% |
| EBITDA Margin | -57.17% | -316.70% | -591.44% | -432.76% | -410.74% |
| Operating Profit Margin | -116.95% | -337.87% | -595.98% | -473.70% | -428.79% |
| Pretax Profit Margin | -92.35% | -363.87% | -643.57% | -470.15% | -434.64% |
| Net Profit Margin | -92.59% | -363.98% | -643.74% | -476.93% | -402.84% |
| Continuous Operations Profit Margin | -92.59% | -363.98% | -643.74% | -476.93% | -402.84% |
| Net Income Per EBT | 100.25% | 100.03% | 100.03% | 101.44% | 92.68% |
| EBT Per EBIT | 78.97% | 107.69% | 107.98% | 99.25% | 101.36% |
| Return on Assets (ROA) | -35.87% | -146.10% | -108.44% | -43.12% | -19.21% |
| Return on Equity (ROE) | -59.42% | -316.66% | -241.78% | -53.17% | -21.49% |
| Return on Capital Employed (ROCE) | -65.83% | -264.41% | -188.19% | -48.49% | -21.70% |
| Return on Invested Capital (ROIC) | -64.63% | -165.21% | -115.34% | -48.04% | -20.02% |
| Return on Tangible Assets | -38.12% | -167.28% | -128.85% | -70.13% | -24.63% |
| Earnings Yield | -316.83% | -340.30% | -353.25% | -30.79% | -8.58% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.48 | 6.45 | 3.74 | 3.71 | 3.38 |
| Payables Turnover | 3.98 | 4.37 | 2.56 | 1.74 | 1.31 |
| Inventory Turnover | 4.08 | 2.73 | 1.16 | 0.73 | 1.14 |
| Fixed Asset Turnover | 1.35 | 1.27 | 1.11 | 0.96 | 0.86 |
| Asset Turnover | 0.39 | 0.40 | 0.17 | 0.09 | 0.05 |
| Working Capital Turnover Ratio | 2.32 | 1.46 | 0.45 | 0.15 | 0.12 |
| Cash Conversion Cycle | 64.25 | 106.56 | 269.59 | 386.09 | 149.88 |
| Days of Sales Outstanding | 66.58 | 56.62 | 97.64 | 98.41 | 108.01 |
| Days of Inventory Outstanding | 89.37 | 133.54 | 314.71 | 496.99 | 320.50 |
| Days of Payables Outstanding | 91.70 | 83.60 | 142.76 | 209.31 | 278.63 |
| Operating Cycle | 155.95 | 190.16 | 412.35 | 595.40 | 428.51 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.00 | -36.22 | -215.69 | -253.87 | -152.86 |
| Free Cash Flow Per Share | -3.00 | -36.28 | -218.60 | -260.58 | -155.97 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -669.15 | -74.03 | -37.80 | -49.27 |
| Capital Expenditure Coverage Ratio | 0.00 | -669.15 | -74.03 | -37.80 | -49.27 |
| Operating Cash Flow Coverage Ratio | -2.36 | -2.52 | -1.58 | -10.70 | -6.72 |
| Operating Cash Flow to Sales Ratio | -0.57 | -2.24 | -3.47 | -4.49 | -4.00 |
| Free Cash Flow Yield | -196.20% | -209.70% | -192.77% | -29.75% | -8.69% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.32 | -0.29 | -0.28 | -3.25 | -11.65 |
| Price-to-Sales (P/S) Ratio | 0.29 | 1.07 | 1.82 | 15.49 | 46.95 |
| Price-to-Book (P/B) Ratio | 0.19 | 0.93 | 0.68 | 1.73 | 2.50 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.51 | -0.48 | -0.52 | -3.36 | -11.50 |
| Price-to-Operating Cash Flow Ratio | -0.51 | -0.48 | -0.53 | -3.45 | -11.74 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | -0.01 | -0.04 | 0.35 |
| Enterprise Value Multiple | -0.75 | -0.52 | -0.60 | -3.63 | -11.24 |
| Enterprise Value | 12.26M | 51.04M | 127.28M | 437.27M | 830.26M |
| EV to EBITDA | -0.75 | -0.52 | -0.60 | -3.63 | -11.24 |
| EV to Sales | 0.43 | 1.66 | 3.52 | 15.73 | 46.17 |
| EV to Free Cash Flow | -0.75 | -0.74 | -1.00 | -3.41 | -11.31 |
| EV to Operating Cash Flow | -0.75 | -0.74 | -1.02 | -3.50 | -11.54 |
| Tangible Book Value Per Share | 7.36 | 13.49 | 107.15 | 266.38 | 540.06 |
| Shareholders’ Equity Per Share | 8.16 | 18.59 | 165.68 | 507.26 | 716.46 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.01 | 0.07 |
| Revenue Per Share | 5.24 | 16.17 | 62.23 | 56.55 | 38.21 |
| Net Income Per Share | -4.85 | -58.87 | -400.59 | -269.69 | -153.94 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.01 | 0.93 |
| Interest Burden | 1.01 | 1.00 | 1.02 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.40 | 0.81 | 1.50 | 1.76 | 1.25 |
| SG&A to Revenue | 0.99 | 1.68 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.16 | 0.32 | 0.42 | 0.81 | 0.54 |
| Income Quality | 0.62 | 0.62 | 0.54 | 0.94 | 0.99 |
Currency in USD